We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-64.00 | -0.60% | 10,678.00 | 10,688.00 | 10,690.00 | 10,780.00 | 10,674.00 | 10,756.00 | 1,773,970 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 27.83 | 165.72B |
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that its cancer treatment Enhertu reduced the risk of disease progression or death by 72% in patients with HER2-positive metastatic breast cancer.
HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.
The U.K. pharmaceutical giant said that the DESTINY-Breast03 Phase 3 trial showed that Enhertu demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed antibody drug conjugate currently approved to treat patients with HER2-positive unresectable--unable to be removed by surgery--and/or metastatic breast cancer previously treated with trastuzumab and a taxane--a type of drug that blocks cell growth.
"The high and consistent benefit seen across efficacy endpoints and key subgroups of patients receiving Enhertu in DESTINY-Breast03 is remarkable and supports the potential of Enhertu to become the new standard of care for those who have previously been treated for HER2-positive metastatic breast cancer," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 20, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions